These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 38296597)

  • 1. PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity.
    Moraes Ribeiro E; Secker KA; Nitulescu AM; Schairer R; Keppeler H; Wesle A; Schmid H; Schmitt A; Neuber B; Chmiest D; Podavini S; Märklin M; Klimovich B; Schmitt M; Korkmaz F; Lengerke C; Schneidawind C; Schneidawind D
    J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38296597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD19-chimeric antigen receptor-invariant natural killer T cells transactivate NK cells and reduce alloreactivity.
    Wesle A; Moraes Ribeiro E; Schairer R; Keppeler H; Korkmaz F; Radszuweit P; Bieber K; Lengerke C; Schneidawind D; Schneidawind C
    Cytotherapy; 2024 Aug; ():. PubMed ID: 39269404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity.
    Ghosh A; Smith M; James SE; Davila ML; Velardi E; Argyropoulos KV; Gunset G; Perna F; Kreines FM; Levy ER; Lieberman S; Jay HV; Tuckett AZ; Zakrzewski JL; Tan L; Young LF; Takvorian K; Dudakov JA; Jenq RR; Hanash AM; Motta AC; Murphy GF; Liu C; Schietinger A; Sadelain M; van den Brink MR
    Nat Med; 2017 Feb; 23(2):242-249. PubMed ID: 28067900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Traversing the bench to bedside journey for iNKT cell therapies.
    O'Neal J; Mavers M; Jayasinghe RG; DiPersio JF
    Front Immunol; 2024; 15():1436968. PubMed ID: 39170618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Culture-Expanded Human Invariant Natural Killer T Cells Suppress T-Cell Alloreactivity and Eradicate Leukemia.
    Schmid H; Schneidawind C; Jahnke S; Kettemann F; Secker KA; Duerr-Stoerzer S; Keppeler H; Kanz L; Savage PB; Schneidawind D
    Front Immunol; 2018; 9():1817. PubMed ID: 30127790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Maintenance therapy following CD19 CAR-T treatment for relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation].
    Jiang YL; Li Q; Pu YD; Jiang YY; Yuan T; Deng Q; Li YM; Han MZ; Zhai WH
    Zhonghua Xue Ye Xue Za Zhi; 2020 Jun; 41(6):495-501. PubMed ID: 32654464
    [No Abstract]   [Full Text] [Related]  

  • 7. Development of optimized cytotoxicity assays for assessing the antitumor potential of CAR-T cells.
    Eugene-Norbert M; Cuffel A; Riou G; Jean L; Blondel C; Dehayes J; Bisson A; Giverne C; Brotin E; Denoyelle C; Poulain L; Boyer O; Martinet J; Latouche JB
    J Immunol Methods; 2024 Feb; 525():113603. PubMed ID: 38147898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.
    Davies JK; Singh H; Huls H; Yuk D; Lee DA; Kebriaei P; Champlin RE; Nadler LM; Guinan EC; Cooper LJ
    Cancer Res; 2010 May; 70(10):3915-24. PubMed ID: 20424114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy.
    Li YR; Zhou Y; Kim YJ; Zhu Y; Ma F; Yu J; Wang YC; Chen X; Li Z; Zeng S; Wang X; Lee D; Ku J; Tsao T; Hardoy C; Huang J; Cheng D; Montel-Hagen A; Seet CS; Crooks GM; Larson SM; Sasine JP; Wang X; Pellegrini M; Ribas A; Kohn DB; Witte O; Wang P; Yang L
    Cell Rep Med; 2021 Nov; 2(11):100449. PubMed ID: 34841295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting.
    Rotolo A; Caputo VS; Holubova M; Baxan N; Dubois O; Chaudhry MS; Xiao X; Goudevenou K; Pitcher DS; Petevi K; Kachramanoglou C; Iles S; Naresh K; Maher J; Karadimitris A
    Cancer Cell; 2018 Oct; 34(4):596-610.e11. PubMed ID: 30300581
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.
    O'Neal J; Cooper ML; Ritchey JK; Gladney S; Niswonger J; González LS; Street E; Haas GJ; Carter A; Amayta PN; Gao F; Lee BH; Choi D; Berrien-Elliott M; Zhou A; Fehniger TA; Rettig MP; DiPersio JF
    Blood Adv; 2023 Oct; 7(20):6009-6022. PubMed ID: 37399471
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human invariant natural killer T cells promote tolerance by preferential apoptosis induction of conventional dendritic cells.
    Schmid H; Ribeiro EM; Secker KA; Duerr-Stoerzer S; Keppeler H; Dong R; Munz T; Schulze-Osthoff K; Hailfinger S; Schneidawind C; Schneidawind D
    Haematologica; 2022 Feb; 107(2):427-436. PubMed ID: 33440919
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of PD-1 inhibitor Nivolumab on the proliferation and cytotoxicity of anti-CD19 chimeric antigen receptor T cells].
    Zhu HB; Deng Q; Zhang R; Jiang YY; Meng JX; Zhao MF; Li YM; Cui R
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jul; 39(7):584-588. PubMed ID: 30122019
    [No Abstract]   [Full Text] [Related]  

  • 15. Secretion of human soluble programmed cell death protein 1 by chimeric antigen receptor-modified T cells enhances anti-tumor efficacy.
    Zhang A; Sun Y; Wang S; Du J; Gao X; Yuan Y; Zhao L; Yang Y; Xu L; Lei Y; Duan L; Xu C; Ma L; Wang J; Hu G; Chen H; Wang Q; Hu L; Zhang B
    Cytotherapy; 2020 Dec; 22(12):734-743. PubMed ID: 32684339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogeneic CAR-T cells with of HLA-A/B and TRAC disruption exhibit promising antitumor capacity against B cell malignancies.
    Chen X; Tan B; Xing H; Zhao X; Ping Y; Zhang Z; Huang J; Shi X; Zhang N; Lin B; Cao W; Li X; Zhang X; Li L; Jiang Z; Zhang M; Li W; Liu M; Du B; Zhang Y
    Cancer Immunol Immunother; 2024 Jan; 73(1):13. PubMed ID: 38231412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic Hematopoietic Cell Transplantation after Chimeric Antigen Receptor T Cell Therapy in Large B Cell Lymphoma.
    Fried S; Shouval R; Walji M; Flynn JR; Yerushalmi R; Shem-Tov N; Danylesko I; Tomas AA; Fein JA; Devlin SM; Sauter CS; Shah GL; Kedmi M; Jacoby E; Shargian L; Raanani P; Yeshurun M; Perales MA; Nagler A; Avigdor A; Shimoni A
    Transplant Cell Ther; 2023 Feb; 29(2):99-107. PubMed ID: 36343892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
    Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
    J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming.
    Simonetta F; Lohmeyer JK; Hirai T; Maas-Bauer K; Alvarez M; Wenokur AS; Baker J; Aalipour A; Ji X; Haile S; Mackall CL; Negrin RS
    Clin Cancer Res; 2021 Nov; 27(21):6054-6064. PubMed ID: 34376537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.